Study: NCT03260491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (FL-DP)
Description: HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (FL-DP)
Description: HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (FL-DP)
Description: HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (FL-DP)
Description: HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (CTM-1 Lyo-DP)
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (CTM-1 Lyo-DP)
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (CTM-1 Lyo-DP)
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (CTM-1 Lyo-DP)
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (CTM-3 Lyo-DP)
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd (CTM-3 Lyo-DP)
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.